


*The Comprehensive Care Sustainability Collaborative (CCSC) is aimed at promoting the HTC integrated care model and augmenting the sustainability of HTCs via enhanced connectivity with payers.*

## Numerous Factors Threaten HTC Sustainability and Revenue Opportunities



## Changes in Market Trends

While many HTCs depend on 340B program revenue from the sale of clotting factor replacement products to maintain and grow their integrated care programs, in recent years, it has become more challenging to access specialty pharmacy contracts due to current trends including:


- Factor coverage is shifting from the medical to the pharmacy benefit, limiting participation in agreements among certain HTCs
- Increased vertical integration, such as PBMs acquiring their own specialty pharmacies and working with plan sponsors to set up narrow networks for distribution of high-cost specialty drugs

PBM: Pharmacy Benefit Manager

## CCSC: A Hemophilia Quality Improvement and Cost Management Initiative

Sponsored by National Bleeding Disorders Foundation

- CCSC was formed in 2014 with a prominent group of HTC directors, clinicians, and administrators along with payer/managed care medical and pharmacy directors
- The goal of CCSC is to augment the sustainability of HTCs through the following:



# Benefits of CCSC Participation for HTC



Strengthen your engagement with payers by communicating the value of HTCs




Understand what motivates payers to make network inclusion and exclusion decisions



Identify data that quantify the value of the integrated care model

## CCSC Connects HTCs with Payers and Conducts Outreach to Align These Groups of Stakeholders



Provided by



In Partnership with



CCSC is supported by charitable donations from founding supporter Takeda, and additional support from BioMarin, Biotechnology Innovation Organization, Bleeding & Clotting Disorders Institute, CSL Behring, Genentech, Inc., Gulf States Hemophilia and Thrombophilia Center, Louisiana Center for Bleeding and Clotting Disorders, Sanofi, and Spark Therapeutics.

Copay Accumulator Adjustment Program (CAAP) Outreach is supported by AbbVie, Inc.

© 2024 National Bleeding Disorders Foundation. All Rights Reserved.